

## HEMATOLOGICAL STUDIES IN LIVER CIRRHOSIS

Xalimova Yulduz Saloxiddinovna

Asia Internatoinal University

<https://doi.org/10.5281/zenodo.15242474>

**Abstract.** Liver cirrhosis is a chronic and progressive condition marked by fibrosis and nodular regeneration of hepatic tissue, ultimately leading to hepatic failure. Besides the direct effects on liver structure and function, cirrhosis has systemic implications, particularly in hematological homeostasis. Hematological abnormalities are frequently observed in cirrhotic patients and may serve as markers of disease progression and complications. This article provides a comprehensive overview of hematological disturbances in liver cirrhosis, their underlying mechanisms, diagnostic tools, and clinical relevance in patient management.

**Keywords:** structure, chronic viral hepatitis, the synthesis of clotting factors, non-alcoholic steatohepatitis (NASH), synthetic.

## ГЕМАТОЛОГИЧЕСКИЕ ИССЛЕДОВАНИЯ ПРИ ЦИРРОЗЕ ПЕЧЕНИ

**Аннотация.** Цирроз печени — хроническое и прогрессирующее заболевание, характеризующееся фиброзом и узелковой регенерацией печеночной ткани, что в конечном итоге приводит к печеночной недостаточности. Помимо прямого воздействия на структуру и функцию печени, цирроз имеет системные последствия, особенно в гематологическом гомеостазе. Гематологические нарушения часто наблюдаются у пациентов с циррозом и могут служить маркерами прогрессирования заболевания и осложнений. В этой статье представлен всесторонний обзор гематологических нарушений при циррозе печени, их основных механизмов, диагностических инструментов и клинической значимости в лечении пациентов.

**Ключевые слова:** структура, хронический вирусный гепатит, синтез факторов свертывания, неалкогольный стеатогепатит (НАСГ), синтетический.

**Introduction**

Liver cirrhosis constitutes the final and irreversible phase of various chronic liver diseases, including alcoholic liver disease, chronic viral hepatitis, non-alcoholic steatohepatitis (NASH), and autoimmune hepatitis. As the disease progresses, normal hepatic architecture is replaced by fibrous tissue and regenerative nodules, severely impairing the liver's ability to perform essential metabolic, synthetic, and detoxifying functions.

The hematological system is particularly sensitive to changes in liver function. The liver plays a crucial role in hematopoiesis, iron storage, the synthesis of clotting factors, and regulation of platelet production through thrombopoietin. Consequently, liver dysfunction results

in a broad range of hematological abnormalities that include anemia, thrombocytopenia, leukopenia, and coagulopathies. Recognizing and managing these complications is fundamental to the treatment of patients with cirrhosis.

### 1. Anemia in Liver Cirrhosis

Anemia affects approximately 75% of patients with decompensated cirrhosis and can significantly impact quality of life and clinical outcomes. The pathogenesis of anemia in cirrhosis is multifactorial and includes:

**Chronic gastrointestinal bleeding**, particularly from esophageal and gastric varices, portal hypertensive gastropathy, or hemorrhoids.

**Hypersplenism**, which results in the increased destruction of erythrocytes due to splenomegaly and blood cell sequestration.

**Nutritional deficiencies**, such as iron, folate, and vitamin B12, which are common in alcoholics and malnourished individuals.

**Bone marrow suppression** due to alcohol toxicity or chronic inflammation.

**Hemolytic anemia**, such as spur cell anemia in advanced liver disease, where altered lipid metabolism changes the erythrocyte membrane.

Clinically, anemia may be asymptomatic or present with fatigue, pallor, and reduced exercise tolerance. Laboratory evaluation includes complete blood count (CBC), reticulocyte count, iron studies, and vitamin levels. Treatment is based on the underlying cause: iron or vitamin supplementation, blood transfusions, or control of variceal bleeding.

### 2. Thrombocytopenia

Thrombocytopenia is one of the earliest and most consistent hematologic findings in liver cirrhosis. Platelet counts often drop below  $150,000/\mu\text{L}$ , and severe thrombocytopenia ( $<50,000/\mu\text{L}$ ) is observed in advanced stages.

#### Etiology:

**Splenic sequestration** due to portal hypertension results in pooling and destruction of platelets.

**Decreased hepatic production of thrombopoietin (TPO)**, a key regulator of platelet production.

**Bone marrow suppression** by alcohol or infections (e.g., hepatitis C virus).

**Autoimmune mechanisms**, including the presence of antiplatelet antibodies in some cirrhotic patients.

#### Clinical significance:

Thrombocytopenia increases the risk of spontaneous mucosal bleeding, complicates invasive diagnostic or therapeutic procedures (e.g., liver biopsy, paracentesis), and may delay

antiviral or chemotherapy treatments. In cases of severe thrombocytopenia, platelet transfusions or thrombopoietin receptor agonists (e.g., eltrombopag, avatrombopag) may be required.

### 3. Leukopenia

Leukopenia, particularly neutropenia, is often seen in cirrhosis, particularly in the context of hypersplenism. While mild leukopenia may be asymptomatic, significant reductions can impair host defense mechanisms and increase susceptibility to infections such as spontaneous bacterial peritonitis (SBP), pneumonia, and urinary tract infections.

In cirrhotic patients with leukopenia, clinicians should remain vigilant for signs of sepsis, especially in hospitalized or immunocompromised individuals. Management includes infection prophylaxis (e.g., norfloxacin in SBP prevention) and addressing splenomegaly or bone marrow suppression.

### 4. Coagulopathy and Hemostatic Imbalance

The liver is the primary site for the synthesis of most coagulation factors (except factor VIII and von Willebrand factor). In cirrhosis, impaired hepatic synthetic function results in:

**Reduced levels of clotting factors** (factors II, V, VII, IX, and X).

**Diminished synthesis of anticoagulant proteins** (antithrombin, protein C, and protein S).

**Prolonged prothrombin time (PT) and elevated international normalized ratio (INR).**

Historically, cirrhosis was viewed as a hypocoagulable state. However, recent studies show that patients may also have a **prothrombotic tendency**, particularly due to elevated levels of factor VIII and reduced levels of natural anticoagulants. As a result, cirrhosis is now considered a “**rebalanced**” hemostatic state, where both bleeding and thrombosis can occur.

#### **Clinical implications:**

Increased risk of gastrointestinal bleeding and hemorrhagic complications.

Paradoxically, risk of **portal vein thrombosis** or **deep vein thrombosis**.

Routine use of fresh frozen plasma (FFP) for prophylactic correction of INR is not recommended unless active bleeding is present or procedures are planned.

### 5. Diagnostic Tools and Laboratory Assessment

Thorough hematologic evaluation is critical in all cirrhotic patients. Recommended tests include:

**CBC:** to assess for anemia, leukopenia, and thrombocytopenia.

**Peripheral blood smear:** may show spur cells, macrocytosis, or evidence of hemolysis.

**Iron studies:** serum iron, ferritin, transferrin saturation.

**Vitamin B12 and folate levels.**

**Coagulation profile:** PT, INR, activated partial thromboplastin time (aPTT), fibrinogen.

**Thrombopoietin levels** (if available).

**Liver and spleen ultrasound:** to assess for splenomegaly and portal hypertension.

**Bone marrow biopsy:** indicated if pancytopenia or hematological malignancy is suspected.

## 6. Therapeutic Considerations

Treatment of hematologic abnormalities in cirrhosis is based on etiology and severity:

**Anemia:** iron supplementation (oral or IV), erythropoiesis-stimulating agents (rarely), blood transfusions, and control of bleeding sources.

**Thrombocytopenia:** platelet transfusions, TPO receptor agonists, splenectomy in refractory cases (rare).

**Leukopenia:** infection prophylaxis, granulocyte colony-stimulating factor (G-CSF) in select cases.

**Coagulopathy:** vitamin K (if deficiency is suspected), FFP for active bleeding, antifibrinolytics, or anticoagulation therapy if thrombosis is present.

Importantly, **liver transplantation** remains the definitive treatment for end-stage liver disease and can reverse many of the hematological abnormalities over time.

## Conclusion

Hematological disturbances are common in patients with liver cirrhosis and reflect complex pathophysiological processes involving hypersplenism, impaired liver synthesis, nutritional deficiencies, and altered bone marrow function. These abnormalities not only contribute to the morbidity and mortality of cirrhosis but also influence treatment strategies and prognosis.

Comprehensive hematological assessment should be incorporated into the routine evaluation of cirrhotic patients. Understanding the dynamic balance between bleeding and thrombosis, recognizing the risk of infection due to leukopenia, and identifying correctable causes of anemia are essential for effective clinical management. Interdisciplinary collaboration among hepatologists, hematologists, and critical care specialists is vital to optimize patient outcomes.

## REFERENCES

1. Schuppan D, Afdhal NH. Liver cirrhosis. *Lancet*. 2008;371(9615):838–851.
2. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. *Lancet*. 2014;383(9930):1749–1761.
3. Qamar AA, Grace ND. Thrombocytopenia in chronic liver disease. *Clin Liver Dis*.

- 2009;13(1):43–58.
4. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. *N Engl J Med.* 2011;365(2):147–156.
  5. McHutchison JG, Bacon BR. Anemia and its management in chronic liver disease. *Hepatology.* 2006;44(2):513–520.
  6. Халимова, Ю. С. (2021). MORPHOFUNCTIONAL ASPECTS OF THE HUMAN BODY IN THE ABUSE OF ENERGY DRINKS. *Новый день в медицине, 5(37), 208-210.*
  7. Халимова, Ю. С. (2022). МОРФОФУНКЦИОНАЛЬНЫЕ ОСОБЕННОСТИ ЯИЧНИКОВ КРЫС ПРИ ВОЗДЕЙСТВИИ КОФЕИН СОДЕРЖАЩИХ НАПИТОК. *Gospodarka i Innowacje., 23, 368-374.*
  8. Salokhiddinova, X. Y. (2023). INFLUENCE OF EXTERNAL FACTORS ON THE MALE REPRODUCTIVE SYSTEM. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE, 3(10), 6-13.*
  9. Халимова, Ю. С., & Шокиров, Б. С. (2022). МОРФОФУНКЦИОНАЛЬНЫЕ ОСОБЕННОСТИ ВНУТРЕННИХ ОРГАНОВ ПРИ ХРОНИЧЕСКОМ АЛКОГОЛИЗМЕ. *Scientific progress, 3(2), 782-789.*
  10. Halimova, Y. S. (2023). Morphological Aspects of Rat Ovaries When Exposed to Caffeine Containing Drink. *BEST JOURNAL OF INNOVATION IN SCIENCE, RESEARCH AND DEVELOPMENT, 2(6), 294-300.*
  11. Halimova, Y. S., Shokirov, B. S., & Khasanova, D. A. (2023). Reproduction and Viability of Female Rat Offspring When Exposed To Ethanol. *Procedia of Engineering and Medical Sciences, 32-35.*
  12. Salokhiddinova, H. Y. (2023). Morphological Features of the Human Body in Energy Drink Abuse. *EUROPEAN JOURNAL OF INNOVATION IN NONFORMAL EDUCATION, 3(5), 51-53.*
  13. Халимова, Ю. С., & Шокиров, Б. С. (2022). СОВРЕМЕННЫЕ ДАННЫЕ О МОРФО-ФУНКЦИОНАЛЬНЫХ АСПЕКТАХ ЧЕЛОВЕЧЕСКОГО ОРГАНИЗМА ПРИ ЗЛОУПОТРЕБЛЕНИИ ЭНЕРГЕТИЧЕСКИМИ НАПИТКАМИ. *PEDAGOGS journali, 4(1), 154-161.*
  14. Halimova, Y. S. (2023). Morphofunctional Aspects of Internal Organs in Chronic Alcoholism. *AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI, 2(5), 83-87.*
  15. Shokirov, B. S. (2021). Halimova Yu. S. Antibiotic-induced rat gut microbiota dysbiosis and salmonella resistance Society and innovations.

16. Халимова, Ю. С., & Шокиров, Б. С. (2021). Репродуктивность и жизнеспособность потомства самок крыс при различной длительности воздействия этанола. In *Актуальные вопросы современной медицинской науки и здравоохранения: Материалы VI Международной научно-практической конференции молодых учёных и студентов, посвященной году науки и технологий, (Екатеринбург, 8-9 апреля 2021): в 3-х т.*. Федеральное государственное бюджетное образовательное учреждение высшего образования «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации.
17. Khalimova, Y. S. BS Shokirov Morphological changes of internal organs in chronic alcoholism. *Middle European scientific bulletin*, 12-2021.
18. Шокиров, Б. С., & Халимова, Ю. С. (2022). ДИСБИОЗ ВЫЗВАННЫЙ АНИБИОТИКАМИ КИШЕЧНОЙ МИКРОБИОТЫ КРЫС И УСТОЙЧИВОСТЬ К САЛМОНЕЛЛАМ. *Scientific progress*, 3(2), 766-772.
19. Salokhiddinovna, X. Y. (2023). Clinical Features of the Course of Vitamin D Deficiency in Women of Reproductive Age. *EUROPEAN JOURNAL OF INNOVATION IN NONFORMAL EDUCATION*, 3(11), 28-31.
20. Шокиров, Б., & Халимова, Ю. (2021). Антибиотик-индуцированный дисбиоз микробиоты кишечника крыс и резистентность к сальмонеллам. *Общество и инновации*, 2(4/S), 93-100.
21. Salokhiddinovna, X. Y. (2023). MORPHOLOGICAL CHANGES IN PATHOLOGICAL FORMS OF ERYTHROCYTES. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, 3(11), 20-24.
22. Saloxiddinovna, X. Y. (2023). ERITROTSITLAR PATOLOGIK SHAKLLARINING MORFOLOGIK O'ZGARISHLARI. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 33(1), 167-172.
23. Шокиров, Б., & Халимова, Ю. (2021). Antibiotic-induced rat gut microbiota dysbiosis and salmonella resistance. *Общество и инновации*, 2(4/S), 93-100.
24. Шокиров, Б. С., & Халимова, Ю. С. (2021). Пищеварительная функция кишечника после коррекции экспериментального дисбактериоза у крыс бифидобактериями. In *Актуальные вопросы современной медицинской науки и здравоохранения: Материалы VI Международной научно-практической конференции молодых учёных и студентов, посвященной году науки и технологий, (Екатеринбург, 8-9 апреля 2021): в 3-х т.*. Федеральное государственное бюджетное образовательное учреждение высшего образования «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации.

25. Salokhiddinovna, X. Y. (2023). Anemia of Chronic Diseases. *Research Journal of Trauma and Disability Studies*, 2(12), 364-372.
26. Salokhiddinovna, X. Y. (2023). MALLORY WEISS SYNDROME IN DIFFUSE LIVER LESIONS. *Journal of Science in Medicine and Life*, 1(4), 11-15.
27. Salohiddinovna, X. Y. (2023). SURUNKALI KASALLIKLARDA UCHRAYDIGAN ANEMIYALAR MORFO-FUNKSIONAL XUSUSIYATLARI. *Ta'lim innovatsiyasi va integratsiyasi*, 10(3), 180-188.
28. Халимова, Ю. С. (2024). КЛИНИКО-МОРФОЛОГИЧЕСКИЕ ОСОБЕННОСТИ ВИТАМИНА D В ФОРМИРОВАНИЕ ПРОТИВОИНФЕКЦИОННОГО ИММУНИТА. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 36(3), 86-94.
29. Saloxiddinovna, X. Y. (2024). CLINICAL FEATURES OF VITAMIN D EFFECTS ON BONE METABOLISM. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 36(5), 90-99.
30. Saloxiddinovna, X. Y. (2024). CLINICAL AND MORPHOLOGICAL ASPECTS OF AUTOIMMUNE THYROIDITIS. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 36(5), 100-108.
31. Saloxiddinovna, X. Y. (2024). MORPHOFUNCTIONAL FEATURES BLOOD MORPHOLOGY IN AGE-RELATED CHANGES. *Лучшие интеллектуальные исследования*, 14(4), 146-158.
32. Saloxiddinovna, X. Y. (2024). CLINICAL MORPHOLOGICAL CRITERIA OF LEUKOCYTES. *Лучшие интеллектуальные исследования*, 14(4), 159-167.
33. Saloxiddinovna, X. Y. (2024). Current Views of Vitamin D Metabolism in the Body. *Best Journal of Innovation in Science, Research and Development*, 3(3), 235-243.
34. Saloxiddinovna, X. Y. (2024). MORPHOFUNCTIONAL FEATURES OF THE STRUCTURE AND DEVELOPMENT OF THE OVARIES. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, 4(4), 220-227.
35. Saloxiddinovna, X. Y. (2024). Modern Views on the Effects of the Use of Cholecalciferol on the General Condition of the Bod. *JOURNAL OF HEALTHCARE AND LIFE-SCIENCE RESEARCH*, 3(5), 79-85.
36. Халимова, Ю. С., & Хафизова, М. Н. (2024). МОРФО-ФУНКЦИОНАЛЬНЫЕ И КЛИНИЧЕСКИЕ АСПЕКТЫ СТРОЕНИЯ И РАЗВИТИЯ ЯИЧНИКОВ (ОБЗОР ЛИТЕРАТУРЫ). *TADQIQOTLAR. UZ*, 40(5), 188-198.

37. Халимова, Ю. С. (2024). Морфологические Особенности Поражения Печени У Пациентов С Синдромом Мэллори-Вейса. *Journal of Science in Medicine and Life*, 2(6), 166-172.
38. Xalimova, Y. S. (2024). Morphology of the Testes in the Detection of Infertility. *Journal of Science in Medicine and Life*, 2(6), 83-88.
39. KHALIMOVA, Y. S. (2024). MORPHOFUNCTIONAL CHARACTERISTICS OF TESTICULAR AND OVARIAN TISSUES OF ANIMALS IN THE AGE ASPECT. *Valeology: International Journal of Medical Anthropology and Bioethics*, 2(9), 100-105.
40. Salokhiddinovna, K. Y. (2024). IMMUNOLOGICAL CRITERIA OF REPRODUCTION AND VIABILITY OF FEMALE RAT OFFSPRING UNDER THE INFLUENCE OF ETHANOL. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, 4(10), 200-205.
41. Salokhiddinovna, K. Y., Saifiloevich, S. B., Barnoevich, K. I., & Hikmatov, A. S. (2024). THE INCIDENCE OF AIDS, THE DEFINITION AND CAUSES OF THE DISEASE. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 55(2), 195-205.
42. Nematilloevna, K. M., & Salokhiddinovna, K. Y. (2024). IMPORTANT FEATURES IN THE FORMATION OF DEGREE OF COMPARISON OF ADJECTIVES IN LATIN. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 55(2), 150-157.
43. Saloxiddinovna, X. Y., & Ne'matillaevna, X. M. (2024). FEATURES OF THE STRUCTURE OF THE REPRODUCTIVE ORGANS OF THE FEMALE BODY. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 55(2), 179-183.
44. Хафизова, М. Н., & Халимова, Ю. С. (2024). ИСПОЛЬЗОВАНИЕ ЧАСТОТНЫХ ОТРЕЗКОВ В НАИМЕНОВАНИЯХ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ В ФАРМАЦЕВТИКЕ. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 55(2), 172-178.
45. Хафизова, М. Н., & Халимова, Ю. С. (2024). МОТИВАЦИОННЫЕ МЕТОДЫ ПРИ ОБУЧЕНИИ ЛАТЫНИ И МЕДИЦИНСКОЙ ТЕРМИНОЛОГИИ. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 55(2), 165-171.
46. Халимова, Ю. С., & Хафизова, М. Н. (2024). ОСОБЕННОСТИ СОЗРЕВАНИЕ И ФУНКЦИОНИРОВАНИЕ ЯИЧНИКОВ. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 55(2), 188-194.



47. Халимова, Ю. С., & Хафизова, М. Н. (2024). КЛИНИЧЕСКИЕ АСПЕКТЫ ЛИЦ ЗЛОУПОТРЕБЛЯЮЩЕЕСЯ ЭНЕРГЕТИЧЕСКИМИ НАПИТКАМИ. *TADQIQOTLAR. UZ*, 40(5), 199-207.
48. Халимова, Ю. С., & Хафизова, М. Н. (2024). кафедра Клинических наук Азиатский международный университет Бухара, Узбекистан. *Modern education and development*, 10(1), 60-75.
49. Халимова, Ю. С., & Хафизова, М. Н. (2024). КЛИНИЧЕСКИЕ ОСОБЕННОСТИ ЗАБОЛЕВАНИЙ ВНУТРЕННИХ ОРГАНОВ У ЛИЦ, СТРАДАЮЩИХ АЛКОГОЛЬНОЙ ЗАВИСИМОСТЬЮ. *TADQIQOTLAR. UZ*, 40(5), 240-250.
50. Халимова, Ю. С., & Хафизова, М. Н. (2024). МОРФО-ФУНКЦИОНАЛЬНЫЕ И КЛИНИЧЕСКИЕ АСПЕКТЫ ФОРМИРОВАНИЯ КОЖНЫХ ПОКРОВОВ. *Modern education and development*, 10(1), 76-90.
51. Khalimova, Y. S. (2024). Features of Sperm Development: Spermatogenesis and Fertilization. *American Journal of Bioscience and Clinical Integrity*, 1(11), 90-98.
52. Salokhiddinova, K. Y., & Nematilloeva, K. M. (2024). MODERN MORPHOLOGY OF NEMATODIETIC ORGANS. *Modern education and development*, 16(9), 50-60.
53. Khalimova, Y. (2025). MORPHOLOGY OF PATHOLOGICAL FORMS OF PLATELETS. *Modern Science and Research*, 4(2), 749-759.
54. Salokhiddinova, K. Y., & Nematilloeva, K. M. (2025). MODERN MORPHOLOGY OF NEMATODIETIC ORGANS. *Modern education and development*, 19(2), 498-508.
55. Халимова, Ю. С., & Хафизова, М. Н. (2025). СОВРЕМЕННАЯ МОРФОЛОГИЯ КРОВЕТВОРНЫХ ОРГАНОВ. *Modern education and development*, 19(2), 487-497.
56. Халимова, Ю. С., & Хафизова, М. Н. (2025). ГИСТОЛОГИЧЕСКАЯ СТРУКТУРНАЯ МОРФОЛОГИЯ НЕФРОНОВ. *Modern education and development*, 19(2), 464-475.
57. Saloxiddinova, X. Y., & Nematilloeva, X. M. (2025). NEFRONLARNING GISTOLOGIK TUZILISH MORFOLOGIYASI. *Modern education and development*, 19(2), 509-520.
58. Saloxiddinova, X. Y., & Ne'matilloeva, X. M. (2025). QON YARATUVCHI A'ZOLARNING ZAMONAVIY MORFOLOGIYASI. *Modern education and development*, 19(2), 476-486.
59. Khalimova, Y. (2025). MODERN CONCEPTS OF BIOCHEMISTRY OF BLOOD COAGULATION. *Modern Science and Research*, 4(3), 769-777.